MIRCERA (Methoxy Polyethylene Glycol-Epoetin Beta)
Continuous erythropoietin receptor activator for the treatment of anemia in chronic kidney disease
MIRCERA is a long-acting erythropoiesis-stimulating agent (ESA) used to treat symptomatic anemia caused by chronic kidney disease (CKD) in adults and children aged 3 months and older. Unlike shorter-acting ESAs, MIRCERA can be administered once monthly during maintenance therapy, offering greater convenience for patients on long-term treatment. It works by stimulating the bone marrow to produce more red blood cells, helping to correct low hemoglobin levels.
Quick Facts
Key Takeaways
- MIRCERA treats anemia caused by chronic kidney disease by stimulating red blood cell production in the bone marrow, similar to the natural hormone erythropoietin.
- Its extended half-life allows once-monthly dosing during maintenance, reducing the treatment burden for patients compared to other ESAs that require more frequent injections.
- The target hemoglobin level is 10–12 g/dL; exceeding this range increases the risk of cardiovascular events including heart attack, stroke, and blood clots.
- Blood pressure must be closely monitored as hypertension is the most common side effect, and uncontrolled high blood pressure is a contraindication.
- MIRCERA should be stored in a refrigerator (2–8°C) but can be kept at room temperature (below 30°C) for up to one month if needed.
What Is MIRCERA and What Is It Used For?
MIRCERA (methoxy polyethylene glycol-epoetin beta) belongs to a class of medications known as erythropoiesis-stimulating agents (ESAs). It is a continuous erythropoietin receptor activator (CERA) that has been specifically engineered through recombinant DNA technology to have a significantly longer duration of action than conventional erythropoietins. This extended half-life—approximately 130 hours after subcutaneous injection—is what enables the once-monthly dosing schedule that distinguishes MIRCERA from earlier ESAs.
Chronic kidney disease frequently leads to anemia because the kidneys normally produce erythropoietin, a hormone that signals the bone marrow to manufacture red blood cells. As kidney function declines, erythropoietin production falls, resulting in progressively fewer red blood cells and lower hemoglobin concentrations. This anemia manifests as fatigue, weakness, shortness of breath, reduced exercise tolerance, and impaired quality of life. Left untreated, CKD-associated anemia can contribute to cardiac complications including left ventricular hypertrophy and heart failure.
MIRCERA addresses this deficit by binding to the erythropoietin receptor on erythroid progenitor cells in the bone marrow, stimulating their proliferation, differentiation, and survival. The result is an increase in the production of red blood cells and a corresponding rise in hemoglobin levels. The medication is approved for the treatment of symptomatic anemia associated with CKD in adult patients who may or may not be receiving dialysis, and in children aged 3 months to under 18 years who have been stabilized on maintenance ESA therapy.
It is important to understand that MIRCERA is specifically indicated for CKD-related anemia. Its safety and efficacy have not been established for anemia caused by other conditions, including cancer-related anemia. Patients with CKD who also have cancer should discuss the potential risks and benefits of ESA therapy with their physician, as ESAs may have an adverse effect in the setting of malignancy.
What Should You Know Before Taking MIRCERA?
Contraindications
MIRCERA must not be used in the following circumstances:
- Hypersensitivity: If you are allergic to methoxy polyethylene glycol-epoetin beta or any of the excipients in the formulation, including sodium dihydrogen phosphate monohydrate, sodium sulfate, mannitol, methionine, poloxamer 188, or water for injections.
- Uncontrolled hypertension: If you have high blood pressure that cannot be adequately managed with medication or dietary measures. Treatment must not begin until blood pressure is brought under control.
Pure red cell aplasia (PRCA)—a condition where the body stops or significantly reduces production of red blood cells due to anti-erythropoietin antibodies—has been reported in patients treated with ESAs, including MIRCERA. If your physician suspects or confirms the presence of these antibodies, MIRCERA treatment must not be initiated or must be discontinued immediately.
Warnings and Precautions
Before and during MIRCERA treatment, several important precautions must be observed. Your healthcare provider will carefully weigh the benefits and risks of therapy and will conduct regular monitoring.
Cardiovascular risk: Hemoglobin levels should not exceed 12 g/dL (7.45 mmol/L). Targeting or maintaining hemoglobin levels above this threshold has been associated with an increased risk of serious cardiovascular events, including myocardial infarction (heart attack), stroke, venous thromboembolism, and death. Your doctor will initiate treatment only when hemoglobin is 10 g/dL or lower and will aim to maintain levels between 10 and 12 g/dL.
Dose response monitoring: If you do not respond adequately to MIRCERA, your physician will investigate potential causes rather than simply escalating the dose. Repeated dose increases without adequate response may further increase cardiovascular risk. Iron deficiency, infection, inflammation, blood loss, and other factors should be evaluated as possible explanations for poor response.
Blood pressure: Hypertension is the most frequently reported adverse effect. Blood pressure will be monitored before and throughout treatment. If blood pressure rises to levels that cannot be controlled with appropriate antihypertensive therapy or dietary modifications, MIRCERA treatment may need to be reduced or discontinued.
Iron status: Your doctor will assess serum ferritin and transferrin saturation before and during treatment. Adequate iron stores are essential for an optimal response to MIRCERA. Supplemental iron therapy may be prescribed if your levels are insufficient.
Hepatitis C co-infection: Patients receiving interferon and ribavirin for hepatitis C should discuss this with their physician before starting MIRCERA. The combination of ESAs with interferon and ribavirin has been associated with loss of ESA efficacy and, in rare cases, development of PRCA.
Cancer patients with CKD: Patients who have both chronic kidney disease and active cancer should be aware that ESAs may have a negative impact on their oncologic condition. Alternative approaches to anemia management should be discussed with the treating physician.
Severe skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment. Early signs include reddish-purple target-shaped or round patches on the trunk, often with central blistering, as well as mouth, throat, nose, and genital sores. These may be preceded by fever and flu-like symptoms. If you develop any serious skin reaction, stop MIRCERA immediately and seek urgent medical attention.
Healthy individuals: MIRCERA must not be used by people who do not have anemia due to CKD. Misuse can lead to dangerously elevated hemoglobin levels, causing life-threatening cardiovascular or thromboembolic complications.
Children and Adolescents
MIRCERA may be used in children and adolescents aged 3 months to under 18 years who have anemia related to CKD. However, pediatric use is restricted to patients who have already been stabilized on maintenance ESA therapy. Children should not self-administer MIRCERA; injections must be given by a healthcare professional or a trained adult caregiver. Speak with your child's healthcare team before initiating or switching to MIRCERA.
Pregnancy and Breastfeeding
MIRCERA has not been studied in pregnant or breastfeeding women. If you are pregnant, think you may be pregnant, or are planning a pregnancy, inform your doctor before starting treatment. Your physician will determine whether the benefits of treatment outweigh the potential risks. Similarly, if you are breastfeeding or plan to breastfeed, your doctor will advise whether to discontinue breastfeeding or to discontinue treatment. Animal studies have not shown evidence of impaired fertility, but the potential risk in humans is unknown.
Driving and Operating Machinery
MIRCERA is not expected to affect your ability to drive or operate machinery. However, if you experience dizziness or other symptoms related to your underlying anemia, exercise caution when performing activities that require alertness.
MIRCERA contains less than 1 mmol (23 mg) sodium per mL, meaning it is essentially sodium-free. This is relevant for patients on sodium-restricted diets.
How Does MIRCERA Interact with Other Drugs?
No pharmacokinetic or pharmacodynamic interaction studies have been performed with MIRCERA. Based on the available clinical data, there is no evidence that MIRCERA influences or is influenced by concomitant medications. Nevertheless, it is essential to inform your doctor or pharmacist about all medicines you are currently using, have recently used, or might use in the future.
While direct drug-drug interactions have not been identified, several therapeutic considerations are relevant when MIRCERA is used alongside other treatments in the management of CKD:
| Drug / Treatment | Consideration | Clinical Relevance |
|---|---|---|
| Iron supplements | Often required as adjunctive therapy to ensure adequate iron stores for erythropoiesis | Complementary; iron supplementation enhances MIRCERA efficacy |
| Antihypertensive agents | Blood pressure may rise during MIRCERA treatment, potentially requiring dose adjustment of antihypertensives | Monitor blood pressure closely; adjust antihypertensive therapy as needed |
| Interferon + Ribavirin | Combination with ESAs in hepatitis C patients has led to reduced ESA efficacy and rare cases of PRCA | Discuss alternative anemia management strategies with physician |
| Anticoagulants (e.g., heparin) | Increased red blood cell mass may affect heparin dosing requirements during dialysis | Dialysis heparin dose may need reassessment as hemoglobin rises |
| Phosphate binders | No known interaction; commonly co-administered in CKD patients | No dose adjustment required |
MIRCERA is not affected by food or drink. It can be administered regardless of meals. The medication is given by injection (subcutaneously or intravenously), so oral absorption interactions are not applicable.
What Is the Correct Dosage of MIRCERA?
Always use MIRCERA exactly as prescribed by your doctor. Treatment should be initiated under the supervision of a healthcare professional experienced in the management of anemia in CKD patients. The overarching principle of dosing is to use the lowest effective dose to maintain hemoglobin between 10 and 12 g/dL, minimizing the risk of cardiovascular complications.
Adults Not Currently Receiving an ESA
Non-Dialysis Patients
The recommended starting dose is 1.2 micrograms per kg body weight administered as a subcutaneous injection once monthly. Alternatively, your doctor may prescribe 0.6 micrograms per kg given once every two weeks either subcutaneously or intravenously.
Dialysis Patients
The recommended starting dose is 0.6 micrograms per kg body weight administered once every two weeks, either subcutaneously or intravenously. Once anemia is corrected and hemoglobin levels are stable, your doctor may change the dosing interval to once monthly.
Adults Switching from Another ESA
Conversion from Previous ESA
If you are already being treated with another erythropoiesis-stimulating agent (such as epoetin alfa, epoetin beta, or darbepoetin alfa), your physician will calculate your MIRCERA starting dose based on the last dose of your previous medication. MIRCERA will be administered once monthly, and the first dose will be scheduled on the date your next injection of the previous ESA was due.
Children and Adolescents (3 months to <18 years)
MIRCERA is indicated in pediatric patients aged 3 months to under 18 years who have CKD-related anemia and have already been stabilized on maintenance ESA therapy. The dose is calculated by the treating physician based on the child's previous ESA dose. Children and adolescents should not self-inject; administration must be carried out by a healthcare professional or a trained adult caregiver. Pediatric patients may or may not be receiving dialysis.
Elderly Patients
No specific dose adjustment is required for elderly patients. However, as older adults are more likely to have comorbidities and may be at higher cardiovascular risk, careful hemoglobin monitoring and conservative dosing strategies are particularly important in this population.
Dose Adjustments
Your physician may increase or decrease the dose, or temporarily suspend treatment, to keep your hemoglobin within the target range. Dose adjustments should not be made more frequently than once per month. If hemoglobin rises too quickly (more than 2 g/dL in four weeks) or exceeds 12 g/dL, the dose should be reduced by approximately 25%. If hemoglobin continues to rise despite dose reduction, treatment should be temporarily withheld.
| Patient Group | Starting Dose | Route | Frequency |
|---|---|---|---|
| Adults (non-dialysis, ESA-naive) | 1.2 mcg/kg or 0.6 mcg/kg | SC (or IV for 0.6 mcg/kg) | Once monthly or every 2 weeks |
| Adults (dialysis, ESA-naive) | 0.6 mcg/kg | SC or IV | Every 2 weeks, then monthly |
| Adults (switching from ESA) | Based on previous ESA dose | SC or IV | Once monthly |
| Children 3 months to <18 years | Based on previous ESA dose | SC or IV | As determined by physician |
Missed Dose
If you forget to take a dose of MIRCERA, take it as soon as you remember and speak with your doctor about when to schedule your next dose. Do not take a double dose to make up for a missed one. Because MIRCERA has a long duration of action, a brief delay in dosing is unlikely to cause an immediate drop in hemoglobin, but consistent adherence to the prescribed schedule is important for optimal results.
Overdose
If you suspect you have taken more MIRCERA than prescribed, contact your doctor or pharmacist immediately. Overdose may lead to excessively elevated hemoglobin levels, which can cause serious cardiovascular complications. Your physician may need to monitor your blood counts closely and may temporarily suspend treatment. There is no specific antidote for MIRCERA overdose; management is supportive and symptomatic, which may include phlebotomy if hemoglobin rises to dangerous levels.
MIRCERA can be injected subcutaneously (under the skin) in the abdomen, arm, or thigh, or administered intravenously (into a vein). For subcutaneous self-injection, adults must receive proper training from a healthcare professional. Rotate injection sites each time, maintaining at least 3 cm distance from the previous site. Do not inject into areas that are bruised, tender, red, hard, or scarred.
What Are the Side Effects of MIRCERA?
Like all medicines, MIRCERA can cause side effects, although not everybody gets them. The following is a summary of reported adverse reactions organized by frequency. If you experience any side effects, especially if they are severe or persistent, speak with your doctor, pharmacist, or nurse.
Common
May affect up to 1 in 10 patients
- Hypertension (high blood pressure)
Uncommon
May affect up to 1 in 100 patients
- Headache
- Vascular access thrombosis (blood clot in the dialysis access site)
- Thrombocytopenia (low platelet count)
- Thrombosis (blood clots)
Rare
May affect up to 1 in 1,000 patients
- Hypertensive encephalopathy (very high blood pressure causing headache, confusion, speech difficulties, seizures)
- Pulmonary embolism (blood clot in the lungs)
- Maculopapular skin rash (red rash with flat and raised areas)
- Hot flush
- Hypersensitivity reactions (allergic reactions including wheezing, difficulty breathing, facial or throat swelling, dizziness, or fainting)
Contact your doctor or emergency services immediately if you experience signs of a severe allergic reaction (anaphylaxis) such as difficulty breathing, swelling of the face, tongue, or throat, rapid heartbeat, or collapse. Also seek urgent care for signs of severe skin reactions (Stevens-Johnson syndrome or toxic epidermal necrolysis), which present as widespread reddish-purple patches, blistering, and sores of the mouth, throat, or eyes, often preceded by fever.
Additional Safety Information
In clinical studies, patients receiving MIRCERA experienced a mild decrease in platelet counts. Post-marketing reports have also documented thrombocytopenia (platelet counts below normal levels). Your physician will monitor your blood counts as part of routine treatment surveillance.
As with all ESAs, MIRCERA carries a risk of thromboembolic events, including deep vein thrombosis, pulmonary embolism, and vascular access clotting. This risk is particularly relevant when hemoglobin levels are allowed to rise above the recommended target range. Maintaining hemoglobin within 10–12 g/dL is therefore essential to minimize these risks.
Pure red cell aplasia (PRCA) is a rare but serious adverse effect that has been observed with all ESAs, including MIRCERA. If you develop unexplained fatigue, weakness, or shortness of breath despite treatment, inform your doctor. Investigation may include blood tests and bone marrow examination. If PRCA is confirmed, MIRCERA must be discontinued permanently, and no other ESA should be administered.
Reports of anaphylactic reactions and other hypersensitivity reactions, including cases of Stevens-Johnson syndrome and toxic epidermal necrolysis, have been received during post-marketing surveillance of epoetin-class products. These are rare but potentially life-threatening conditions.
How Should You Store MIRCERA?
Proper storage of MIRCERA is essential to maintain the effectiveness and safety of the medication. The following guidelines should be strictly followed:
- Refrigeration: Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
- Do not freeze: Freezing may damage the protein structure of the active ingredient and render the medication ineffective.
- Light protection: Keep the pre-filled syringe in its outer carton to protect it from light.
- Room temperature option: You may remove MIRCERA from the refrigerator and store it at room temperature (not exceeding 30°C / 86°F) for a single continuous period of up to one month. Once removed from refrigeration, do not return it to the refrigerator. Mark the date you removed it to track the one-month window.
- Expiry date: Do not use after the expiration date printed on the outer carton and the pre-filled syringe label (marked "EXP"). The expiry date refers to the last day of that month.
- Visual inspection: Before use, inspect the solution. Only use if it is clear, colorless to slightly yellowish, and free from visible particles. Do not use if the solution is cloudy, discolored, or contains particulate matter.
- Disposal: Do not dispose of used syringes in household waste. Place them in an approved sharps disposal container and follow local guidelines for the disposal of pharmaceutical waste.
- Keep out of reach of children.
What Does MIRCERA Contain?
Active Ingredient
The active substance is methoxy polyethylene glycol-epoetin beta, a PEGylated form of recombinant human erythropoietin. The PEG (polyethylene glycol) moiety extends the molecule's half-life, enabling less frequent dosing. Each pre-filled syringe contains 30, 50, 75, 100, 120, 150, 200, or 250 micrograms in 0.3 mL, or 360 micrograms in 0.6 mL of solution.
Inactive Ingredients (Excipients)
- Sodium dihydrogen phosphate monohydrate (buffer)
- Sodium sulfate
- Mannitol (E421) (osmolality adjuster)
- Methionine (stabilizer)
- Poloxamer 188 (surfactant)
- Water for injections
Presentation and Packaging
MIRCERA is supplied as a clear, colorless to slightly yellowish solution in pre-filled glass syringes fitted with a laminated plunger rod stopper and a rubber closure, equipped with a 27G½ needle. Each syringe contains either 0.3 mL or 0.6 mL of solution. Pre-filled syringes are not designed for partial-dose administration. MIRCERA is available in packs of 1 syringe for all strengths, and in multipacks of 3 x 1 syringes for the 30, 50, and 75 microgram/0.3 mL strengths. Not all pack sizes may be available in all markets.
The marketing authorization holder is Roche Registration GmbH, based in Grenzach-Wyhlen, Germany, and the manufacturer is Roche Pharma AG at the same location.
Frequently Asked Questions About MIRCERA
MIRCERA is used to treat symptomatic anemia (low red blood cell count causing fatigue, weakness, and shortness of breath) caused by chronic kidney disease (CKD). It works by stimulating the bone marrow to produce more red blood cells, raising hemoglobin levels. It is approved for adults and children aged 3 months to under 18 years. In children, it is used only in those already stabilized on another erythropoiesis-stimulating agent (ESA).
One of the key advantages of MIRCERA is its extended duration of action. During the initial correction phase, it is typically given once every two weeks. Once your hemoglobin has stabilized within the target range, your doctor will usually switch to once-monthly dosing. This less frequent administration schedule is a significant convenience compared to other ESAs that may require weekly or three-times-weekly injections.
Yes, adults can self-administer MIRCERA subcutaneously (under the skin) after receiving proper training from a healthcare professional. Suitable injection sites include the abdomen (avoiding the navel area), the thigh, and the upper arm. Rotate the injection site each time, using a new site at least 3 centimeters from the previous one. Children under 18 should not self-inject; the medication must be given by a healthcare professional or a trained adult caregiver.
If you miss a dose, take it as soon as you remember and contact your doctor to reschedule your next dose. Do not take a double dose. Because MIRCERA has a long half-life (approximately 130 hours), a short delay is unlikely to cause an immediate drop in hemoglobin. However, consistent adherence to the dosing schedule is important for maintaining stable hemoglobin levels over time.
MIRCERA has not been studied in pregnant women, and its safety during pregnancy has not been established. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, you should inform your doctor before starting MIRCERA. Your physician will carefully weigh the potential benefits against the potential risks and will determine the best treatment approach for your individual situation.
Hypertension (high blood pressure) is the most common side effect of MIRCERA and ESA therapy in general. As hemoglobin rises and the blood becomes more viscous, blood pressure tends to increase. Uncontrolled hypertension can lead to serious complications including hypertensive encephalopathy (a rare but dangerous condition causing severe headache, confusion, and seizures). Your doctor will monitor your blood pressure before and during treatment, and MIRCERA may need to be dose-reduced or discontinued if blood pressure cannot be adequately controlled.
References
- European Medicines Agency (EMA). MIRCERA Summary of Product Characteristics (SmPC). Last updated January 2026. Available at: ema.europa.eu/en/medicines/human/EPAR/mircera
- KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Supplements. 2024;14(1):1–84. doi:10.1016/j.kisu.2024.01.001
- Macdougall IC, et al. CERA (Continuous Erythropoietin Receptor Activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. Journal of the American Society of Nephrology. 2006;17(4):1190–1197.
- Locatelli F, et al. Efficacy and safety of once-monthly continuous erythropoietin receptor activator (MIRCERA) in patients with CKD on dialysis. Nephrology Dialysis Transplantation. 2010;25(3):926–932.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd Edition. 2023.
- National Institute for Health and Care Excellence (NICE). Chronic kidney disease: managing anaemia. NICE guideline [NG8]. Updated 2021.
- Palmer SC, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database of Systematic Reviews. 2014;(12):CD010590.
- Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine. 2006;355(20):2085–2098. (CREATE and CHOIR trials establishing hemoglobin target recommendations)
Medical Editorial Team
Content Authors
iMedic Medical Editorial Team — Specialists in Nephrology, Hematology, and Clinical Pharmacology with documented clinical experience in the management of CKD-related anemia.
Medical Review
Reviewed by the iMedic Medical Review Board according to international guidelines (KDIGO, EMA, NICE, WHO). All medical claims verified against peer-reviewed literature with evidence level 1A.
Last reviewed: February 3, 2026 | Evidence framework: GRADE | Conflict of interest: None declared | Funding: Independent, no commercial sponsorship